• +1-646-491-9876
    • +91-20-67278686

    Search

    Type 2 Diabetes-Pipeline Review H1 2017

    Type 2 Diabetes-Pipeline Review H1 2017

    • Report Code ID: RW0001834315
    • Category Pharmaceuticals
    • No. of Pages 1100
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Type 2 Diabetes - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

    Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 68, 64, 5, 250, 75 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 22 molecules, respectively.

    Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 11
    Type 2 Diabetes - Overview 12
    Type 2 Diabetes - Therapeutics Development 13
    Type 2 Diabetes - Therapeutics Assessment 67
    Type 2 Diabetes - Companies Involved in Therapeutics Development 89
    Type 2 Diabetes - Drug Profiles 198
    Type 2 Diabetes - Dormant Projects 997
    Type 2 Diabetes - Discontinued Products 1025
    Type 2 Diabetes - Product Development Milestones 1035
    Appendix 1043

    List of Tables

    Number of Products under Development for Type 2 Diabetes, H1 2017 69
    Number of Products under Development by Companies, H1 2017 71
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 72
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 73
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 74
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 75
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 76
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 77
    Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 78
    Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 79
    Number of Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 80
    Number of Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 81
    Number of Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 82
    Number of Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 83
    Number of Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 84
    Number of Products under Development by Companies, H1 2017 (Contd..14) , H1 2017 85
    Number of Products under Development by Universities/Institutes, H1 2017 86
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 88
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 89
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017 90
    Products under Development by Companies, H1 2017 91
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 92
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 93
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 94
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 95
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 96
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 97
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 98
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 99
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 100
    Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 101
    Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 102
    Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 103
    Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 104
    Products under Development by Companies, H1 2017 (Contd..14) , H1 2017 105
    Products under Development by Companies, H1 2017 (Contd..15) , H1 2017 106
    Products under Development by Companies, H1 2017 (Contd..16) , H1 2017 107
    Products under Development by Companies, H1 2017 (Contd..17) , H1 2017 108
    Products under Development by Companies, H1 2017 (Contd..18) , H1 2017 109
    Products under Development by Companies, H1 2017 (Contd..19) , H1 2017 110
    Products under Development by Companies, H1 2017 (Contd..20) , H1 2017 111
    Products under Development by Companies, H1 2017 (Contd..21) , H1 2017 112
    Products under Development by Companies, H1 2017 (Contd..22) , H1 2017 113
    Products under Development by Companies, H1 2017 (Contd..23) , H1 2017 114
    Products under Development by Companies, H1 2017 (Contd..24) , H1 2017 115
    Products under Development by Companies, H1 2017 (Contd..25) , H1 2017 116
    Products under Development by Companies, H1 2017 (Contd..26) , H1 2017 117
    Products under Development by Universities/Institutes, H1 2017 118
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 119
    Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 120
    Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017 121
    Products under Development by Universities/Institutes, H1 2017 (Contd..4) , H1 2017 122
    Number of Products by Stage and Target, H1 2017 124
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 125
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 126
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017 127
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017 128
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017 129
    Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017 130
    Number of Products by Stage and Target, H1 2017 (Contd..7) , H1 2017 131
    Number of Products by Stage and Mechanism of Action, H1 2017 133
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 134
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 135
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017 136
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017 137
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017 138
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017 139
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7) , H1 2017 140
    Number of Products by Stage and Route of Administration, H1 2017 142
    Number of Products by Stage and Molecule Type, H1 2017 144
    Type 2 Diabetes - Pipeline by 4P Therapeutics LLC, H1 2017 145
    Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H1 2017 145
    Type 2 Diabetes - Pipeline by Adocia, H1 2017 146
    Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd, H1 2017 146
    Type 2 Diabetes - Pipeline by Aegis Therapeutics LLC, H1 2017 147
    Type 2 Diabetes - Pipeline by AFFiRiS AG, H1 2017 147
    Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2017 148
    Type 2 Diabetes - Pipeline by Allergan Plc, H1 2017 148
    Type 2 Diabetes - Pipeline by Alteogen Inc, H1 2017 149
    Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 149
    Type 2 Diabetes - Pipeline by Amgen Inc, H1 2017 150
    Type 2 Diabetes - Pipeline by Anchor Therapeutics Inc, H1 2017 150
    Type 2 Diabetes - Pipeline by AntriaBio Inc, H1 2017 151
    Type 2 Diabetes - Pipeline by Aphios Corp, H1 2017 151
    Type 2 Diabetes - Pipeline by Araim Pharmaceuticals Inc, H1 2017 152
    Type 2 Diabetes - Pipeline by Arena Pharmaceuticals Inc, H1 2017 152
    Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017 153
    Type 2 Diabetes - Pipeline by ArisGen SA, H1 2017 153
    Type 2 Diabetes - Pipeline by Astellas Pharma Inc, H1 2017 154
    Type 2 Diabetes - Pipeline by AstraZeneca Plc, H1 2017 155
    Type 2 Diabetes - Pipeline by AusBio Ltd, H1 2017 155
    Type 2 Diabetes - Pipeline by Avadel Pharmaceuticals Plc, H1 2017 156
    Type 2 Diabetes - Pipeline by Bayer AG, H1 2017 156
    Type 2 Diabetes - Pipeline by Beta-Cell NV, H1 2017 157
    Type 2 Diabetes - Pipeline by Betagenon AB, H1 2017 157
    Type 2 Diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017 158
    Type 2 Diabetes - Pipeline by Biocon Ltd, H1 2017 158
    Type 2 Diabetes - Pipeline by BioLingus AG, H1 2017 159
    Type 2 Diabetes - Pipeline by BioRestorative Therapies Inc, H1 2017 159
    Type 2 Diabetes - Pipeline by Biozeus, H1 2017 160
    Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017 160
    Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2017 161
    Type 2 Diabetes - Pipeline by Boston Therapeutics Inc, H1 2017 161
    Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2017 162
    Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2017 162
    Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2017 163
    Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017 163
    Type 2 Diabetes - Pipeline by Cardax Inc, H1 2017 164
    Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H1 2017 164
    Type 2 Diabetes - Pipeline by Celon Pharma SA, H1 2017 165
    Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2017 165
    Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017 166
    Type 2 Diabetes - Pipeline by CJ HealthCare Corp, H1 2017 166
    Type 2 Diabetes - Pipeline by CohBar Inc, H1 2017 167
    Type 2 Diabetes - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017 167
    Type 2 Diabetes - Pipeline by ConjuChem LLC, H1 2017 168
    Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017 168
    Type 2 Diabetes - Pipeline by ConSynance Therapeutics Inc, H1 2017 169
    Type 2 Diabetes - Pipeline by Corium International Inc, H1 2017 169
    Type 2 Diabetes - Pipeline by CSL Ltd, H1 2017 170
    Type 2 Diabetes - Pipeline by CureDM Inc, H1 2017 170
    Type 2 Diabetes - Pipeline by CymaBay Therapeutics Inc, H1 2017 171
    Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 171
    Type 2 Diabetes - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 172
    Type 2 Diabetes - Pipeline by Dance Biopharm Inc, H1 2017 172
    Type 2 Diabetes - Pipeline by Delpor Inc, H1 2017 173
    Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H1 2017 173
    Type 2 Diabetes - Pipeline by DiaMedica Therapeutics Inc, H1 2017 174
    Type 2 Diabetes - Pipeline by Diamyd Medical AB, H1 2017 174
    Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals Inc, H1 2017 175
    Type 2 Diabetes - Pipeline by DiscoveryBiomed Inc, H1 2017 175
    Type 2 Diabetes - Pipeline by DNJ Pharma Inc, H1 2017 176
    Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017 176
    Type 2 Diabetes - Pipeline by Elcelyx Therapeutics Inc, H1 2017 177
    Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2017 177
    Type 2 Diabetes - Pipeline by Enteris BioPharma Inc, H1 2017 178
    Type 2 Diabetes - Pipeline by Enzo Biochem Inc, H1 2017 178
    Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H1 2017 179
    Type 2 Diabetes - Pipeline by Esperion Therapeutics Inc, H1 2017 179
    Type 2 Diabetes - Pipeline by Eternygen GmbH, H1 2017 180
    Type 2 Diabetes - Pipeline by Evotec AG, H1 2017 180
    Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 181
    Type 2 Diabetes - Pipeline by Generex Biotechnology Corp, H1 2017 181
    Type 2 Diabetes - Pipeline by Genexine Inc, H1 2017 182
    Type 2 Diabetes - Pipeline by Genfit SA, H1 2017 182
    Type 2 Diabetes - Pipeline by Genmedica Therapeutics SL, H1 2017 183
    Type 2 Diabetes - Pipeline by Genovate Biotechnology Co LTD, H1 2017 183
    Type 2 Diabetes - Pipeline by Geropharm LLC, H1 2017 184
    Type 2 Diabetes - Pipeline by Gilead Sciences Inc, H1 2017 184
    Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H1 2017 185
    Type 2 Diabetes - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017 185
    Type 2 Diabetes - Pipeline by Glucox Biotech AB, H1 2017 186
    Type 2 Diabetes - Pipeline by GW Pharmaceuticals Plc, H1 2017 186
    Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017 187
    Type 2 Diabetes - Pipeline by HanAll Biopharma Co Ltd, H1 2017 187
    Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 188
    Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd, H1 2017 188
    Type 2 Diabetes - Pipeline by HitGen LTD, H1 2017 189
    Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017 189
    Type 2 Diabetes - Pipeline by Immuron Ltd, H1 2017 190
    Type 2 Diabetes - Pipeline by Innopharmax Inc, H1 2017 190
    Type 2 Diabetes - Pipeline by Innovative Targeting Solutions Inc, H1 2017 191
    Type 2 Diabetes - Pipeline by Intarcia Therapeutics Inc, H1 2017 191
    Type 2 Diabetes - Pipeline by Intas Pharmaceuticals Ltd, H1 2017 192
    Type 2 Diabetes - Pipeline by Integral Molecular Inc, H1 2017 192
    Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals Inc, H1 2017 193
    Type 2 Diabetes - Pipeline by Intrexon Corp, H1 2017 193
    Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals Inc, H1 2017 194
    Type 2 Diabetes - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017 194
    Type 2 Diabetes - Pipeline by Islet Sciences Inc, H1 2017 195
    Type 2 Diabetes - Pipeline by Japan Tobacco Inc, H1 2017 195
    Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017 196
    Type 2 Diabetes - Pipeline by Jenrin Discovery Inc, H1 2017 196
    Type 2 Diabetes - Pipeline by JHL Biotech Inc, H1 2017 197
    Type 2 Diabetes - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 197
    Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 198
    Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2017 199
    Type 2 Diabetes - Pipeline by Kadimastem Ltd, H1 2017 200
    Type 2 Diabetes - Pipeline by Kadmon Corp LLC, H1 2017 200
    Type 2 Diabetes - Pipeline by Kareus Therapeutics SA, H1 2017 201
    Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 201
    Type 2 Diabetes - Pipeline by Lead Discovery Center GmbH, H1 2017 202
    Type 2 Diabetes - Pipeline by Leading BioSciences Inc, H1 2017 202
    Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017 203
    Type 2 Diabetes - Pipeline by LG Chem, Ltd., H1 2017 203
    Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals Inc, H1 2017 204

    List of Figures

    Number of Products under Development for Type 2 Diabetes, H1 2017 69
    Number of Products under Development by Companies, H1 2017 70
    Number of Products under Development by Universities/Institutes, H1 2017 86
    Number of Products by Top 10 Targets, H1 2017 123
    Number of Products by Stage and Top 10 Targets, H1 2017 123
    Number of Products by Top 10 Mechanism of Actions, H1 2017 132
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 132
    Number of Products by Top 10 Routes of Administration, H1 2017 141
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017 141
    Number of Products by Top 10 Molecule Types, H1 2017 143
    Number of Products by Stage and Top 10 Molecule Types, H1 2017 143
    4P Therapeutics LLC
    Addex Therapeutics Ltd
    Adocia
    Advinus Therapeutics Ltd
    Aegis Therapeutics LLC
    AFFiRiS AG
    Alize Pharma SAS
    Allergan Plc
    Alteogen Inc
    Amarantus Bioscience Holdings Inc
    Amgen Inc
    Anchor Therapeutics Inc
    AntriaBio Inc
    Aphios Corp
    Araim Pharmaceuticals Inc
    Arena Pharmaceuticals Inc
    Arisaph Pharmaceuticals Inc
    ArisGen SA
    Astellas Pharma Inc
    AstraZeneca Plc
    AusBio Ltd
    Avadel Pharmaceuticals Plc
    Bayer AG
    Beta-Cell NV
    Betagenon AB
    Betta Pharmaceuticals Co Ltd
    Biocon Ltd
    BioLingus AG
    BioRestorative Therapies Inc
    Biozeus
    Biscayne Pharmaceuticals Inc
    Boehringer Ingelheim GmbH
    Boston Therapeutics Inc
    Braasch Biotech LLC
    Bristol-Myers Squibb Company
    C4X Discovery Holdings PLC
    Cadila Pharmaceuticals Ltd
    Cardax Inc
    Carmot Therapeutics Inc
    Celon Pharma SA
    Chipscreen Biosciences Ltd
    Chong Kun Dang Pharmaceutical Corp
    CJ HealthCare Corp
    CohBar Inc
    Concenter BioPharma Silkim Ltd
    ConjuChem LLC
    Connexios Life Sciences Pvt Ltd
    ConSynance Therapeutics Inc
    Corium International Inc
    CSL Ltd
    CureDM Inc
    CymaBay Therapeutics Inc
    Daewoong Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    Dance Biopharm Inc
    Delpor Inc
    Diabetology (Products) Ltd
    DiaMedica Therapeutics Inc
    Diamyd Medical AB
    Diasome Pharmaceuticals Inc
    DiscoveryBiomed Inc
    DNJ Pharma Inc
    Dong-A Socio Holdings Co Ltd
    Elcelyx Therapeutics Inc
    Eli Lilly and Company
    Enteris BioPharma Inc
    Enzo Biochem Inc
    Epichem Pty Ltd
    Esperion Therapeutics Inc
    Eternygen GmbH
    Evotec AG
    F. Hoffmann-La Roche Ltd
    Generex Biotechnology Corp
    Genexine Inc
    Genfit SA
    Genmedica Therapeutics SL
    Genovate Biotechnology Co LTD
    Geropharm LLC
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Glide Pharmaceutical Technologies Ltd
    Glucox Biotech AB
    GW Pharmaceuticals Plc
    Hadasit Medical Research Services & Development Ltd
    HanAll Biopharma Co Ltd
    Hanmi Pharmaceuticals Co Ltd
    Heptares Therapeutics Ltd
    HitGen LTD
    Hyundai Pharmaceutical Co Ltd
    Immuron Ltd
    Innopharmax Inc
    Innovative Targeting Solutions Inc
    Intarcia Therapeutics Inc
    Intas Pharmaceuticals Ltd
    Integral Molecular Inc
    Intercept Pharmaceuticals Inc
    Intrexon Corp
    Ionis Pharmaceuticals Inc
    Ironwood Pharmaceuticals Inc
    Islet Sciences Inc
    Japan Tobacco Inc
    Jeil Pharmaceutical Co Ltd
    Jenrin Discovery Inc
    JHL Biotech Inc
    Jiangsu Hansoh Pharmaceutical Group Co Ltd
    Jiangsu Hengrui Medicine Co Ltd
    Johnson & Johnson
    Kadimastem Ltd
    Kadmon Corp LLC
    Kareus Therapeutics SA
    Kissei Pharmaceutical Co Ltd
    Lead Discovery Center GmbH
    Leading BioSciences Inc
    Lexicon Pharmaceuticals Inc
    LG Chem, Ltd.
    Ligand Pharmaceuticals Inc
    LipimetiX Development Inc
    Lonestar Heart Inc
    Longevity Biotech Inc
    Luye Pharma Group Ltd
    Magnus Life Ltd
    Medesis Pharma SA
    Medestea Research & Production SpA
    MedImmune LLC
    Medlab Clinical Ltd
    Melior Discovery Inc
    Mellitech SAS
    Merck & Co Inc
    Mesoblast Ltd
    Metabolic Solutions Development Company LLC
    Metabolys SAS
    Metacrine Inc
    Mitsubishi Tanabe Pharma Corp
    Moderna Therapeutics Inc
    Naia Ltd
    Neurimmune Holding AG
    Neurocrine Biosciences Inc
    NGM Biopharmaceuticals Inc
    Nordic Bioscience A/S
    Novapeutics LLC
    Novartis AG
    NovaTarg Therapeutics Inc
    Novo Nordisk A/S
    Noxxon Pharma AG
    Omeros Corp
    OPKO Biologics Ltd
    OPKO Health Inc
    Oramed Pharmaceuticals Inc
    Paras Biopharmaceuticals Finland Oy
    Peptron Inc
    Pfizer Inc
    PharmaCyte Biotech Inc
    PharmaIN Corp
    Pila Pharma AB
    Poxel SA
    Prometheon Pharma LLC
    ProMetic Life Sciences Inc
    Purzer Pharmaceutical Co Ltd
    Reata Pharmaceuticals Inc
    ReCyte Therapeutics Inc
    reMYND NV
    Renova Therapeutics Inc
    Reset Therapeutics Inc
    Saniona AB
    Sanofi
    Sanwa Kagaku Kenkyusho Co Ltd
    SATT Conectus Alsace SAS
    SBI Pharmaceuticals Co Ltd
    Seres Therapeutics Inc
    Serodus ASA
    Serometrix LLC
    Sevion Therapeutics Inc
    Shenzhen HighTide Biopharmaceutical Ltd
    Shionogi & Co Ltd
    Sihuan Pharmaceutical Holdings Group Ltd
    Sirona Biochem Corp
    SJT Molecular Research SL
    SK Chemicals Co Ltd
    Sprint Bioscience AB
    Sumitomo Dainippon Pharma Co Ltd
    Taisho Pharmaceutical Holdings Co Ltd
    Takeda Pharmaceutical Company Ltd
    Tasly Pharmaceutical Group Co Ltd
    Teijin Pharma Ltd
    The Medicines Company
    Theracos Inc
    Thermalin Diabetes LLC
    Toray Industries Inc
    Torrent Pharmaceuticals Ltd
    Transgene Biotek Ltd
    TTY Biopharm Company Ltd
    Uni-Bio Science Group Ltd
    Valeant Pharmaceuticals International Inc
    ViaCyte Inc
    Vichem Chemie Research Ltd
    Vicore Pharma AB
    Viking Therapeutics Inc
    Vivus Inc
    vTv Therapeutics Inc
    Vybion Inc
    XBiotech Inc
    Xenetic Biosciences Inc
    XL-protein GmbH
    XOMA Corp
    XuanZhu Pharma Co Ltd
    Yuhan Corp
    Yungjin Pharm Co Ltd
    Zafgen Inc
    Zealand Pharma AS
    Zensun (Shanghai) Sci & Tech Co Ltd
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//type-2-diabetes-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//type-2-diabetes-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//type-2-diabetes-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments